PDGFRB and non-small cell lung carcinoma: In subgroup analyses, PDGFR-β+ fibroblast infiltration considerably decreased OS in non-small cell lung cancer (NSCLC), breast and pancreatic cancer, and reduced DFS in breast cancer of patients.